FeesSafety
Pluang+

Monero perpetual contracts show $2.16B open interest, with BTSE dominating 83.7% of the market.

Market News
23 Oct 2026
Tokenpost
View Source
Neutral
Monero perpetual contracts show $2.16B open interest, with BTSE dominating 83.7% of the market.

Open interest in Monero perpetual contracts across 49 venues totals about $2.16 billion, with BTSE holding the largest share at $1.81 billion or 83.7%. This indicates strong market activity centered on BTSE, although exact timing of data is unclear. Open interest measures active positions, but does not reveal whether traders are net long or short. The data highlights BTSE's dominance in Monero trading but lacks precise timestamps for full market analysis.

The story on Monero open interest provides context for readers following cryptocurrency markets. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 23, 2026 19:01 WIB: out of 50 major cryptocurrencies priced on Pluang, 26 rose and 23 fell today. Filecoin (FIL) traded at Rp17.709 with a 1-day change of -3.03%, The Sandbox (SAND) at Rp949 with -2.93%, and Compound (COMP) at Rp438.382 with -2.81%.

More News

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem Corporation reported strong Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and net earnings of $46.7 million, a 16% increase. Growth was driven by all three segments: Human Nutrition and Health, Animal Nutrition and...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App